The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Using optical genome mapping to characterize chromoanagenesis & TP53 mutations in patients with MDS
Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of novel technologies for structural variant profiling in myelodysplastic syndromes (MDS), drawing focus on optical genome mapping (OGM). Dr Kanagal-Shamanna explains that this technique has allowed detailed characterization of chromoanagenesis in these patients, and was found to be associated with the occurrence of adverse prognostic markers including TP53 abnormalities. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Physicians Education Resource: Speakers Bureau; Aptitude Health: Speakers Bureau; Novartis: Consultancy; Amgen: Consultancy.
